U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.2H.H4N
Molecular Weight 209.1543
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMMONIUM CITRATE, MONOBASIC

SMILES

C(C(=O)O)C(CC(=O)O)(C(=O)O)O.N

InChI

InChIKey=BWKOZPVPARTQIV-UHFFFAOYSA-N
InChI=1S/C6H8O7.H3N/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);1H3

HIDE SMILES / InChI

Molecular Formula H4N
Molecular Weight 18.0385
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H5O7
Molecular Weight 189.1
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU

Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

4.94121615E11
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

4.94121615E11
Doses

Doses

DosePopulationAdverse events​
540 mg 1 times / day multiple, oral
Recommended
Dose: 540 mg, 1 times / day
Route: oral
Route: multiple
Dose: 540 mg, 1 times / day
Co-administed with::
Thiamin oral 1.1 mg
Arginine oral 1240 mg
caffeine oral 52 mg
Sources: Page: p.2326
healthy, 24-59
n = 16
Health Status: healthy
Age Group: 24-59
Sex: M+F
Population Size: 16
Sources: Page: p.2326
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity.
1985 Oct
Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.
1993
[Therapeutic use of potassium citrate].
2001
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity.
2013 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. • Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack • Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:18:59 UTC 2021
Edited
by admin
on Sat Jun 26 15:18:59 UTC 2021
Record UNII
CUB9LW4B2O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMMONIUM CITRATE, MONOBASIC
Common Name English
MONOAMMONIUM CITRATE
Systematic Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, AMMONIUM SALT (1:1)
Common Name English
Code System Code Type Description
CAS
4450-94-6
Created by admin on Sat Jun 26 15:18:59 UTC 2021 , Edited by admin on Sat Jun 26 15:18:59 UTC 2021
PRIMARY
ECHA (EC/EINECS)
224-694-1
Created by admin on Sat Jun 26 15:18:59 UTC 2021 , Edited by admin on Sat Jun 26 15:18:59 UTC 2021
PRIMARY
PUBCHEM
165228
Created by admin on Sat Jun 26 15:18:59 UTC 2021 , Edited by admin on Sat Jun 26 15:18:59 UTC 2021
PRIMARY
FDA UNII
CUB9LW4B2O
Created by admin on Sat Jun 26 15:18:59 UTC 2021 , Edited by admin on Sat Jun 26 15:18:59 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE